Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
ACTIVE_NOT_RECRUITING
Status
Conditions
- Systemic Lupus Erythematosus
Interventions
- DRUG: Upadacitinib
- DRUG: Placebo
Sponsor
AbbVie